Iovance reports Q2 2023 net loss $106.5M, cash $317.3M; lifileucel PDUFA Nov 25

IOVANCE BIOTHERAPEUTICS, INC.

2023-Q2 EPS reported -$0.98 revenue$238,000

FDA set PDUFA date Nov 25, 2023 for lifileucel BLA in advanced melanoma under priority review.
Cash $317.3M at June 30; raised ~$161.4M from July public offering; expects funding into end of 2024.
Q2 2023 net loss $106.5M ($0.47/sh) vs $99.3M ($0.63/sh) in Q2 2022; R&D expense up to $86.3M.
Revenue $0.2M from Proleukin acquisition in May 2023; no revenue in prior-year period.
Registrational NSCLC trial IOV-LUN-202: 26.1% ORR in preliminary analysis; enrollment continuing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

IOVANCE BIOTHERAPEUTICS, INC. reported financial results for second quarter and first half 2023.

Period: second quarter and first half 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and an update on recent developments.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-088821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.